Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Regulation on orphan medicinal products was adopted in the European Union in 2000, with the aim of benefiting patients who suffer from serious, rare conditions for which there is currently no satisfactory treatment. This article highlights the outcomes of this regulation, such as the approval of more than 60 orphan drugs, reflects on the experience gained so far and discusses key issues for the next 10 years.
